"Designing Growth Strategies is in our DNA"

Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor & Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist), By Route of Administration (Oral & Parenteral), By Therapy (Chemo, Hormonal, Targeted, and Immuno Therapy), By Disease State (Metastatic Castration-Resistant Prostate Cancer & Non-Metastatic Castration-Resistant Prostate Cancer), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: April 11, 2025 | Format: PDF | Report ID: FBI112008

 

Prostate Cancer Therapeutics Market

Request Now
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
    2. Pipeline Analysis, by Key Players
    3. Overview of Alternative Therapies
    4. Key Start-ups in the Market
    5. New Product Launches, by Key Players
    6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    7. Impact of COVID-19 on the Market
  5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Androgen Receptor Inhibitors
      2. Microtubule Inhibitors
      3. Gonadotropin Releasing Hormone (GnRH) Agonist
      4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
      5. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Therapy
      1. Chemotherapy
      2. Hormonal Therapy
      3. Targeted therapy
      4. Immunotherapy
    4. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer
      2. Non-Metastatic Castration-Resistant Prostate Cancer
    5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2024)
    2. Company Profiles
      1. Astellas Pharma Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability) 
      2. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Johnson & Johnson Services, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Sanofi
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Ferring Pharmaceuticals Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. AbbVie Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. AstraZeneca
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Tolmar, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. Dendreon Pharmaceuticals LLC.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      11. Bayer AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032

Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032

Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032

Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032

Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024 & 2032

Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032

Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032

Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024

Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032

Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024

Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032

Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024

Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2024 & 2032

Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032

Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024

Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032

Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024

Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032

Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024

Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2024

Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032

Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032

Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019–2032

Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019–2032

Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

  • 2019-2032
  • 2024
  • 2019-2023
  • 150
Consulting Services
    How will you benefit from our consulting services ?